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The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of
an eﬀective vaccine. However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven suﬃciently
safe and eﬃcient to warrant commercial development. In recent years, great strides in cellular and molecular immunology have
stimulated creative eﬀorts in controlling herpes infection and disease. However, before moving towards new vaccine strategy,
it is necessary to answer two fundamental questions: (i) why past herpes vaccines have failed? (ii) Why the majority of HSV
seropositive individuals (i.e., asymptomatic individuals) are naturally “protected” exhibiting few or no recurrent clinical disease,
while other HSV seropositive individuals (i.e., symptomatic individuals) have frequent ocular, orofacial, and/or genital herpes
clinical episodes? We recently discovered several discrete sets of HSV-1 symptomatic and asymptomatic epitopes recognized by
CD4+ and CD8+ T cells from seropositive symptomatic versus asymptomatic individuals. These asymptomatic epitopes will
provideasolidfoundationforthedevelopment ofnovel herpesepitope-based vaccine strategy.Herewe provideabriefoverview of
past clinical vaccine trials, outline current progress towards developing a new generation “asymptomatic” clinical herpes vaccines,
and discuss future mucosal “asymptomatic” prime-boost vaccines that could optimize local protective immunity.
1.Introduction
H u m a nh e r p e ss i m p l e xv i r u st y p e1a n dt y p e2( H S V -
1 and HSV-2) infections cause lifelong infections, with a
spectrum of clinical manifestations including cold sores,
genital ulceration, corneal blindness, and encephalitis [1–
10]. Despite multiple approaches of therapy and preven-
tion, HSV-1 and HSV-2 remain among the most common
infectious viral pathogens of man. Current drug therapies
such as oral acyclovir, valacyclovir, or famciclovir can treat
herpes disease but do not prevent future attacks. Historically,
many candidate vaccines that are eﬀective on animal models
of herpes infection turned unsuccessful in clinical trials
[1, 11]. Sampling of past and ongoing vaccine trials is
provided in Table 1. Progress towards an eﬀective vaccine
has stalled in the face of many unknown questions related
to HSV-1 and HSV-2 infection and immunity. Namely,
(i) the cellular and molecular mechanisms behind the
failure of past herpes vaccines remain unknown; (ii) the
cellular and molecular mechanisms that lead the majority
of HSV seropositive individuals to be naturally protected
exhibiting few or no recurrent clinical disease (designated
as asymptomatic individuals), while other HSV seroposi-
tive individuals to have frequent ocular, orofacial, and/or
genital herpes clinical episodes (designated as symptomatic
individuals) remain unknown. Although the majority of
individuals have few or no herpetic disease symptoms, they
still continue shedding HSV all times. An eﬃcient vaccine2 Clinical and Developmental Immunology
Table 1: A sampling of past and ongoing preclinical and clinical vaccine trails.
Company Name Product name Phase of
development∗ HSV vaccine type Mode of action†
Micro-Antigen
Technologies, LLC
“Asymptomatic”
Lipopeptide PC Peptide-based
Self-adjuvanting P&T
AlphaVax, Inc. HSV Vaccine ALPHAVAX PC Alphavirus vector P&T
Genocea Biosciences HSV2 Vaccine GENOCEA PC Undisclosed P&T
Henderson Morley
plc L-particles PC VLP P
Henderson Morley
plc
PREPS (previral DNA
replication enveloped
particles)
PC VLP P
JN International
Medical Corporation
Genital Herpes Vaccine JN
INTERNATIONAL PC Subunit P
Juvaris
Biotherapeutics, Inc
JVRS100 with Herpes
Simplex Virus-2 Antigens PC Subunit gB, gDt, gH/gL
JVRS-100 adjuvant P
Mymetics
Corporation
Herpes Simplex Virus
Vaccine MYMETICS PC VLP P
Sanoﬁ-aventis ACAM529 PC Replication-defective virus P&T
BioVex Inc. ImmunoVEX HSV2
Vaccine I Live-attenuated virus P
Pﬁzer Inc. Genital Herpes DNA
Vaccine PFIZER INC ID N A via PMED T
AuRx, Inc. Theraherb III Live-attenuated virus T
GlaxoSmithKline plc Simplirix F Subunit gD2
SBAS4 adjuvant P
Acuvax Ltd (formerly
Avantogen Limited) HSV 2 ACUVAX D Live-attenuated virus
GPI-0100 adjuvant T
Antigenics Inc. AG702 D Subunit gB2
Human HSP-70 adjuvant T
Antigenics Inc. AG707 D Subunit 32 peptides
Human HSP-70 adjuvant T
BioVex Inc. ImmunoVEX HSV2/HPV
Vaccine D HSV-2/HPV
Combined P&T
Celldex Therapeutics,
Inc. Dl5-29 Vaccine CELLDEX D Live, replication-impaired virus T
Celtic Pharma
Management L.P. DISC Pro D DISC P
Novartis AG Genital Herpes DNA
Vaccine NOVARTIS DD N A T
Celtic Pharma
Management L.P. TAHSV F DISC T
Eli Lilly&Co. Resiquimod ELI LILLY F TLR agonist T
GenVec Inc. Herpes Simplex Virus Type
2 Vaccine GENVEC NA Adenovirus vector P&T
Profectus bioSciences,
Inc.
Herpes Simplex Virus
Vaccine PROFECTUS
BIOSCIENCES
NA DNA with recombinant VSV
boost T
Vical Inc. Herpes Simplex Virus Type
2 Vaccine VICAL NA DNA
Vaxfectin adjuvant T
The table recapitulates the majority of HSV vaccine candidates currently undergoing diﬀerent phases of clinical trials, the companies that are conducting the
trial, the phase of the trial, the type of vaccine, and the therapeutic approach. ∗PC: preclinical, I/III: phase I/phase III, D: discontinued, F: failed, NA: not
available, †P: prophylactic, and T: therapeutic.Clinical and Developmental Immunology 3
would not only relive the patients from herpetic diseases but
also prevent virus reactivation and asymptomatic shedding.
In the past, many vaccine immunotherapies have tried to
stimulatetheimmunesystemagainstherpes,includingabout
a dozen vaccines that reached mid- and late-stage clinical
trials [1]. Every single one of these therapies had generated
much excitement, but, for the most part, none of those
therapies really did protect from herpes. Before devising
more powerful treatments it is imperative to identify (i)
the mechanisms underlying the suboptimal nonprotective
immunity associated with natural infection, (ii) the major
eﬀectors of immunity that control each of the three phases of
herpesinfection(i.e.,acuteandlatent),(iii) thesophisticated
immune evasion strategies employed by HSV-1 and HSV-2
to dampen the immune response, (iv) the protective versus
pathogenic protein (such as glycoprotein gK) Ag(s) among
more than 80 immunogenic HSV proteins, and (v) a safe Ag
delivery system.
Multiple review articles have adequately described and
discussedtheaboveissues[11–15].Thepresentpaperfocuses
on bringing together past and recent published work that
illuminates the current status of clinical herpes vaccine
development. It presents an overview of our own vaccine
approach to produce an “asymptomatic” herpes vaccine.
First, we describe the common presentations of herpes
simplex infections and diseases. Second, we portray the
history of the diﬀerent vaccine formulations that have led to
the rationale for a herpes subunit vaccine. Third,w ed e s c r i b e
theprocessbywhichherpesproteinAgsandderived“asymp-
tomatic” epitopes suitable for inclusion in a multiepitope
vaccine are being selected. Fourth, we shed new light on
how an “asymptomatic” multiepitope lipopeptide vaccine
can be designed to ensure optimal mucosal immunogenicity
and discuss how, after prototype lipopeptide vaccines are
designed, the program will move to the stage of clinical
trials.
2. The Immunoepidemiology of Herpes
HSV-1 and HSV-2 are two closely related members of the
Herpesviridae family and currently rank among the most
prevalent infectious agents of man [16]. Several common
presentations of herpes simplex infections and diseases are
recognized.Genitalherpes:although,bothHSV-1andHSV-2
account for herpes genitalis, a common sexually transmitted
disease (STD), HSV-2 is more severe and has become
more commonly associated with genital herpes [17, 18].
Currently, over 1 billion people around the world—one-
sixth of the world population—are infected with genital
herpes. In the USA alone, at least 40 to 60 million individuals
have been infected by HSV-2. A therapeutic vaccine would
ideally cure many of the adults who often suﬀer frequent
recurrent outbreaks of genital herpes. In addition to the
pain related to herpes ulceration, genital herpes causes a
substantial psychosocial morbidity [18, 19]. Herpes genitalis
contributes to a 2- to 4-fold increased risk of acquiring
human immunodeﬁciency virus (HIV) [3, 20, 21] Genital
herpes in HIV-infected individuals usually needs a longer
duration of antiviral therapy along with continuation of
highly active antiretroviral therapy (HAART). Neonatal
herpes: in some cases, herpes infections are fatal to newborns
and cause neonatal encephalitis [17, 22]. Genital herpes
in late pregnancy increases the risk of neonatal herpes.
Annually, a minimum of 2500 cases of neonatal herpes [23]
and 3000 cases of herpes encephalitis result in signiﬁcant
morbidity and mortality in spite of antiviral therapies. Ocu-
larherpes:ocularinfectionwithHSV-1istheleadingcauseof
corneal blindness worldwide. The corneal scarring induced
by herpes infection often leads to blindness, making HSV-1 a
major cause of virus-induced blindness [4–6, 24–26]. Ocular
infection with HSV-1 can cause other eye diseases ranging
from blepharitis, conjunctivitis, and dendritic keratitis to
disciform stromal edema and necrotizing stromal keratitis
[27–30].IntheUSAalone,over400000peoplehaveahistory
of recurrent ocular HSV episodes requiring doctor visits,
medication and, in severe cases, corneal transplants [28,
29]. Nearly 50,000 new and recurring cases are diagnosed
each year. Shedding of reactivated HSV is estimated to
occur at rates of 3 to 28% in adults who harbor latent
HSV-1 in their sensory neurons [9–12]. However, the vast
majority of these individuals do not experience recurrent
herpetic disease and are designated “asymptomatic patients”
[11, 14, 16]. In contrast, in some individuals (symptomatic
patients), reactivation of latent virus leads to induction of
ineﬀective or “symptomatic” HSV-speciﬁc CD4+ and CD8+
T cells [11, 16, 31]( Figure 1). Recurrent disease ranges from
rare episodes occurring once every 5–10 years to outbreaks
occurring monthly or even more frequently among a small
proportion of subjects [16]. It is not known why ocular
HSV-1 infection is asymptomatic in some individuals and
symptomatic in others or why the frequency and severity of
recurrencesvaryamongsymptomaticpatients.Theshedding
ratesintearsofasymptomaticindividualshavebeenreported
to be as high as 33.5% [13–16]. The immune mechanism(s)
by which asymptomatic patients control herpes disease and
symptomatic patients do not remains to be fully elucidated.
Orofacial herpes: HSV-1-mediated recurrent facial herpes
varies in severity. Symptomatic lesions usually occur on lips
(cold sores), cheeks, within the nose, or on the nasal septum,
which are painful and unpleasant [2, 32–34]. Dermal HSV
infection can occur on any part of the body. Some oro-
facial herpes are asymptomatic or appear as maculopapular
lesions that may subsequently regress or develop into
vesicular lesions, which then scab prior to healing. During
asymptomatic or symptomatic outbreaks, HSV-1 is shed and
can be transmitted to susceptible individuals.
The social and economic burden created by all types of
herpes infection has set direct costs for treatment of these
infectionsintheUSAtoover$400millioneveryyear[16,35].
Current drug therapies can treat the disease but do not
prevent future viral attacks. Thus, novel strategies to treat,
suppress, and prevent HSV infection are needed. An eﬀective
vaccine strategy remains the best hope for controlling the
herpes pandemic. However, in spite of several clinical trials
no vaccine has been proven suﬃciently safe and eﬃcient to
warrant commercial development. It is imperative to know
w h yp a s th e r p e sv a c c i n e sh a v ef a i l e db e f o r ew em o v et o w a r d s
developing a new vaccine strategy.4 Clinical and Developmental Immunology
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Figure 1: The majority of ocular herpes vaccines are injected parenterally, and although they induced strong systemic immune responses,
they failed to generate signiﬁcant local immune responses either in the eye or in trigeminal ganglia (TG). Local immune responses at these
sitesarelikelyneededtoprevent virustransmissionandtoreducevirusreplication,whichshouldeventually reducevirallatency/reactivation
and limit the severity of ocular herpes. Several results from our lab strongly suggest that there is linear association between presence of
“asymptomatic” CD8+ T cells (bleu circles) in the TG and ocular mucosal immune system with the lack of eye disease. In contrast, the
absence of asymptomatic CD8+ T cells and presence of symptomatic CD8+ T cells (red circles) may increase the rate of HSV reactivation and
pathology. The upper panel shows scenario of an asymptomatic HSV-1 infection and the lower panel shows symptomatic HSV-1 infection
and eye disease.
3.Past andCurrentHerpesVaccines
Many classes of herpes vaccines and delivery systems have
been attempted during the last century (Table 1). The
following paragraphs review and discuss the approaches, the
rationale, and the end results associated with some of the
most widely studied herpes vaccines.
3.1. Inactivated and Replication-Defective Vaccines. In the
early 1920s the ﬁrst vaccine was introduced as an inactivatedClinical and Developmental Immunology 5
virus, which was prepared from formalin-treated tissues
of HSV-infected animals [36–38]. A heat- or ultraviolet-
inactivated virus, grown in embryonic eggs, was proposed
later (reviewed in [37, 39]). Subsequent vaccines strate-
gies changed from inactivated to replication-defective HSV
strainssuchasvirulenttypeHSVmutants(i.e.,lackingICP8,
ICP10, dl5-29, or VHS), discontinuously replicating virus
known as “disabled infectious single cycle” or “DISC”, and
a virus with a deletion of UL22, the late gene encoding
glycoproteinH(gH)[40].ADISCHSV-2vaccinehasentered
clinical trials and has been found relatively safe with no
serious adverse eﬀects [41, 42]. Among HSV-seronegative
subjects, dose-dependent induction of T-cell proliferation
was noted four weeks after a single DISC HSV-2 immu-
nization and continued for sixteen weeks after the second
immunization. However, no responses were boosted in HSV-
seropositive subjects. IFN-gamma (Th1) and IL-2 (Th2)
production was also induced in HSV-seronegative persons
in a dose-dependent fashion but not in HSV-seropositive
persons. There was a lack of boosted IgG responses in both
seronegative and seropositive subjects, indicating that DISC
HSV-2 immunization might be shifted to Th1 responses.
However, a recent immunotherapeutic phase II trial showed
no clinical response in HSV-2 DISC-immunized persons
[43].
3.2. Replication Competent Live Virus Vaccines. The replica-
tion competent live virus vaccine approach has the advan-
tages of stimulating a broad immune response (antibody,
CD4+ T cells, and CD8+ T cells) and presenting all epitopes
from the entire genome to generate multiimmune responses.
A case of recurrent human genital HSV-2 disease caused
by a thymidine kinase-deﬁcient, mouse-virulent strain has
been reported [44]. Mutations in thymidine kinase gene do
not attenuate HSV-2 replication suﬃciently when used as
vaccines. A second live attenuated HSV strain developed for
vaccine use is RAV 9395 [45]. This virus was derived from
HSV-2 strain G and contains deletions of both copies of
the virulence factor g134.5, UL55, and UL56. Clinical results
have not been reported for this mutant. The most extensive
humanstudiesareavailablewithattenuatedliveHSVvaccine
strain R7020, created by Branco and Fraser [46]. This virus
was originated from HSV-1 strain F and is attenuated by a
deletionextendingfromUL54(encodingICP27)throughthe
promoter region of ICP4. In a dose escalation study, local
reactions and systemic side eﬀects were noted in HSV-1-
infected persons.
3.3. Recombinant Viral Vectors. An u m b e ro ft r i a l sh a v eb e e n
pursued using recombinant live attenuated adenovirus and
vaccinia recombinant viruses expressing HSV glycoproteins.
These vaccines elicit Ag-speciﬁc CD8+ T cells after a single
immunization [47–49]. Not surprisingly, no major vaccine
company, in the USA or EU, is developing inactivated
live vaccine candidates. An important lesson learned from
the human live vaccine trials is the true feasibility (i.e.,
practicability) of a herpes vaccine.
The recent emergence of new concepts and technologies
in biochemistry, genetics, and immunology has opened up
the way to novel approaches in vaccine development. In the
following paragraphs we bring together both the challenges
and some recent progress made in developing a subunit
herpes vaccine.
3.4. Plasmid (Naked) DNA Vaccines. The concept of using
naked DNA [28] as a vaccine is to introduce herpes antigenic
genes into dendritic cells (DCs) for endogenous processing
and presentation to CD4+ and CD8+ T cells in draining
lymph nodes or into other cells (e.g., epithelial cells) for
cross-presentation by DCs, without the need for a viral
vector.However,thecompetitionwithinviralvectorepitopes
for endogenous processing reduced the eﬃcacy. In addition
the prior immunity to the viral vector and the potential
dangers associated with a live virus are avoided when using
DNA vaccines. Constitutive, tissue-speciﬁc promoters may
be used for selective expression. The results of a number
of plasmid DNA vaccine experiments in animal models of
ocular and genital herpes have been reported [50]. The
delivery of DNA vaccines usually requires high dosage of
DNA plasmid to generate an immune response and often
promotes Th2 response, which would not be expected
to provide optimal protection against HSV infection and
disease [50].
3.5. Recombinant Proteins-Based Subunit Vaccines. HSV has
at least 11 enveloped glycoproteins that are expressed in
infected cells. Among these, gB and gD glycoproteins are
the most used immunogens since these are the dominant
targetsforneutralizingantibodyproductioninHSV-infected
individuals. gB and gD are attractive choices for subunit
vaccines because they are the targets for both humoral
(neutralizingandADCC)andcell-mediatedimmunity (class
I and class II restricted). gB and gD share high sequence
similarity in HSV-1 and HSV-2 and may therefore provide
cross-protection against both HSV-1 and HSV-2 infections.
Despite induction of high neutralizing serum antibody
titers,thelatestclinicalvaccinetrials,usingrecombinantpro-
tein gB and gD along with MF59 adjuvant, showed transient
and partial protection [51–53]. More recently, intramuscular
vaccination with a recombinant HSV-2 gD vaccine, using
MPL as an adjuvant, protected ∼70% of women who were
HSV-1 and HSV-2 seronegative. However, there was no
protectionamongmenoramongHSV-1seropositivewomen
[1, 53]. These results raised important questions regarding
the role of gender-related factors and glycoprotein-based
approach in vaccine eﬃcacy. In this clinical trial, despite the
induction of high neutralizing antibody titers that exceeded
thoseofnaturalimmunity,recurrentdiseasewasnotreduced
suggesting that induction of a vigorous cellular immunity
m i g h tb ec r i t i c a lf o rt h e r a p e u t i cp r o t e c t i o n .
Development of a herpes subunit vaccine has been moti-
vated by previous successes achieved with other pathogens.
However, major hurdles include identiﬁcation of antigens
thatexecutethespeciﬁcityofimmunesystemonHSV-1-and
HSV-2-infected cells without harming uninfected cells. So
far, early clinical trials indicate the need for the identiﬁcation
of target Ags, other than envelope glycoproteins gB and
gD. However, this task is far from complete because of6 Clinical and Developmental Immunology
Table 2: Herpes vaccine formulas used in clinical trials.
Type of HSV
vaccine Formulation Strain Route of
administration Clinical outcome
Live Live HSV Varies Autoinoculation
(i) Unsuccessful
(ii) Recurrence not aﬀected
(iii) Lesions at infection and injection sites
[125, 126]
Live-attenuated Recombinant
R7020
HSV-1(F) and
HSV-2(G) Intramuscular
(i) Unsuccessful
(ii) Poor immunogenicity
(iii) Adverse eﬀects in HSV-1
seropositive individuals [127, 128]
Whole inactivated
Heat inactivated
(Lupidon G and H)
HSV-2(Silow)
and HSV-1(L3) Subcutaneous (i) Statistically signiﬁcant eﬀect on recurrence of
genital and facial herpes [129–131]
Formalin
inactivated —— (ii) No signiﬁcant diﬀerence in recurrence compared
to placebo [132]
Inactivated subunit Skinner: Ac NFU1,
(S-) MRC
HSV-1
(Troisbell) Subcutaneous
(i) Some statistically signiﬁcant results in vaccinated
males
(ii) No consistent eﬃcacy or immunogenicity [133]
Recombinant
subunit
(glycoproteins)
Chiron
gD2gB2-MF59 HSV-2 Intramuscular (i) No signiﬁcant eﬀects on recurrence or shedding
of virus [17]
GlaxoSmithKline
gD2-Alum MPL HSV-2 Intramuscular
(ii) Fewer recurrences
(iii) Higher antibody and gD2-speciﬁc EIA titers
compared to placebo [1, 134]
Disabled infectious
single cycle (DISC) TA-HSV-2
HSV-2(25766)
HSV-1(HFEM)
HSV-1(SC16)
HSV-1(KOS)
HSV-1(tsQ26)
?
(i) Good immunogenicity in early clinical trials
(ii) Unsuccessful phase II trials
(iii) No signiﬁcant diﬀerences in recurrences or
asymptomatic shedding compared to placebo [135]
The table summaries past and present HSV vaccine formulations, HSV-1/2 strains used, route of administration, and clinical outcomes.
the large and complex herpes genome that encodes over
80 polypeptides, each of which could be a potential target
to a protective immune eﬀector. Tegument proteins are
sandwiched in between the envelope and capsid proteins
of HSV and have been reported to be major targets for T-
cell responses. A recent human study that utilized pools of
overlapping synthetic peptides presented to CD8+ Tc e l l s
throughautologousdendriticcellsshowedthattheresponses
to individual open reading frames (ORFs) ranged from ≤5%
to a maximum of 70%. Interestingly, the highest responses
detected in seropositive individuals were focused on six
tegument proteins: UL39, UL25, UL27, ICP0, UL46, and
UL47 in descending order. These six tegument proteins
are therefore considered to be the best candidates for
T-cell-based vaccines [54]. Whether the T-cell responses
of asymptomatic versus symptomatic individuals to these
tegument proteins are similar or diﬀerent remains to be
determined.
Other current vaccine strategies, listed in Table 2, include
the use of virus-like particles (VLPs), adenoviral vectors, and
lipopeptide vaccines; however, very few have been approved
forhumanuse.Twopromisingapproachestoherpesvaccina-
tionarecurrentlybeingpursuedinourandotherslaboratory
b a s e do ne n t i r e l yd i ﬀerent theoretical approaches. The ﬁrst
approach is the subunit vaccines that use “asymptomatic”
epitopes from envelop, tegument, and/or regulatory proteins
withorwithoutadjuvants[2,32].Thesecondapproachisthe
genetically engineered live attenuated vaccine without any
putative neurovirulence or immuno-evasion genes [39, 55,
56]. Few vaccines with these dual modalities have attempted
to provide sterilizing immunity. Nevertheless, prior attempts
at HSV subunit and genetically engineered live attenuated
vaccines have oﬀered important lessons for the design of
clinical and preclinical studies to evaluate vaccines of this
kind.
4. T-Cell-InducingHerpesSimplex
Vaccines—What Isthe Future
Shedding of reactivated HSV-1 and HSV-2 that leads to
recurrent herpetic disease is estimated to occur at rates
of 3 to 28% in adults who harbor latent virus in their
sensory neurons [57–60]. Recurrent disease ranges from
rare episodes occurring once every 5–10 years to outbreaks
occurring monthly or even more frequently among a small
proportion of “symptomatic patients” [61]. For simplic-
ity, one can categorized seropositive individuals based on
the frequency of their recurrent disease into two major
groups: (1) the symptomatic individuals (with a history
of recurrent corneal, genital, and/or orofacial herpetic
disease) and (2) the asymptomatic individuals (never had
any recurrent herpes disease, ocular, genital, orofacial, or
otherwise). The vast majority of seropositive individuals do
not experience recurrent herpetic disease and are designated
“asymptomatic” [59, 61, 62]. In contrast, in “symptomatic”
individuals reactivation of latent virus leads to mild to severeClinical and Developmental Immunology 7
herpetic disease [59, 61, 63]. It is not known why HSV-1
and HSV-2 reactivation/shedding is asymptomatic in some
individuals and symptomatic in others or why the frequency
and severity of recurrent disease vary among symptomatic
individuals. Interestingly, for genital herpes, symptomatic
and asymptomatic patients shed the virus at similar rates
[59, 64]. It is likely to be the same for ocular herpes,
since shedding rates in tears of asymptomatic individuals
h a sb e e nr e p o r t e dt ob ea sh i g ha s3 3 . 5 %[ 61, 62, 65,
66]. The immune mechanism(s) by which asymptomatic
patients control herpetic disease and symptomatic patients
do not remains to be fully elucidated [67]. Identifying these
mechanisms, or at least the viral antigens (Ags) and epitopes
involved, is critical to understanding how to protect against
recurrent herpetic disease and for rational advances in
therapeutic vaccine development. In the most recent clinical
vaccine trials [1], despite recombinant-proteins-based HSV-
2 vaccines induced neutralizing antibody titers that exceeded
those produced by natural immunity, neither symptomatic
infections nor symptomatic recurrences were aﬀected by
therapeutic vaccination. This suggests that induction of
vigorous cellular immunity is critical for better protection
[68, 69]. Thus, T cells appeared to be an important part
of naturally acquired protective immune responses against
herpetic disease, and inducing “asymptomatic” T cells by
vaccination has dominated much of our research eﬀort.
It is likely that Ag exposure during long-term herpes
simplex infections may shape diﬀerent T-cell repertoires
over time, in symptomatic and asymptomatic individuals.
The unique epitope-speciﬁc T-cell repertoire of each symp-
tomatic and asymptomatic individual, known as “private
speciﬁcity” [70–72], is thought to regulate whether herpes
reactivation will result in viral control, asymptomatic persis-
tence, or severe disease. Thus, in symptomatic individuals,
reactivation of latent virus leads to induction of ineﬀective
or “symptomatic” HSV-speciﬁc CD4+ and CD8+ Tc e l l s
[59, 61, 63]. In contrast, in asymptomatic individuals,
reactivation of latent virus leads to induction of protective
or “asymptomatic” HSV-speciﬁc CD4+ and CD8+ Tc e l l s
[59, 61, 63]. A good starting point for the development of an
eﬃcient therapeutic herpes vaccine would be to identify the
matrices of protective or “asymptomatic” Ags and epitopes
strongly recognized by T cells from asymptomatic individu-
als. Our recent ﬁndings support the idea that symptomatic
and asymptomatic individuals have diﬀerent levels of HSV-
speciﬁcT-cellrepertoires([67,73–75],Dervillez,submitted).
We found that T cells from symptomatic and asymptomatic
individuals, with similar HLA, have dramatically diﬀerent
proﬁles of responses to HSV epitopes. A set of human T-
cell epitopes from HSV-1 glycoproteins B and D (gB&gD)
are strongly recognized by T cells from HSV-1-seropositive
asymptomatic individuals, but not by T cells from symp-
tomatic individuals [67, 73–75] .I nc o n t r a s t ,ad i ﬀerent,
nonoverlapping set of gB and gD epitopes are strongly
recognized by T cells from symptomatic but not by T cells
from asymptomatic individuals. However, this diﬀerence is
not due to clonal T-cell deletion since there is not a complete
lack of T-cell response. The “asymptomatic” T-cell precursor
appears to exist in symptomatic patients and vice versa.
Our preclinical vaccine trial in “asymptomatic” HLA
transgenic (HLA Tg) rabbits showed that immunization
with asymptomatic human CD8+ T-cell epitopes from HSV-
1gD induced strong human epitope-speciﬁc CD8+ Tc e l l
responses and reduced HSV-1 shedding in tears and corneal
disease following an ocular challenge [34]. Rabbits support
spontaneous reactivation of HSV-1 at a level similar to
humans (∼10%). Similarly, the rate of recurrent corneal
disease in rabbits is also similar to that of humans. Unfor-
t u n a t e l yt h i sr a t ei sv e r yl o w( <1% of eyes). However, we
have been able to vaccinate HLA transgenic rabbits that
developed recurrent corneal disease (i.e., a “symptomatic”
HLA transgenic rabbits).One rabbit did develop a modest T-
cell response against the “asymptomatic” peptides following
vaccination. This suggests that symptomatic individuals will
be able to respond appropriately to a therapeutic asymp-
tomatic epitope-based vaccine and develop asymptomatic
CD8+ T-cellresponsesspeciﬁctotheasymptomaticepitopes.
Despite “seeing” both “asymptomatic” and “symptomatic”
epitopes (through virus exposure), the vaccinated asymp-
tomatic individuals may not appear to revert to mixed T-
cell populations but rather develop mainly the protective
asymptomatic responses. The results also provide tangible
preclinical evidence that immunization of “symptomatic”
individuals with an “asymptomatic” epitope-based vaccine
will likely boost “asymptomatic” T-cell responses in symp-
tomatic patients (as it did in HLA Tg rabbits) and that
may be suﬃcient to stop or reduce recurrent disease, upon
encounter with the virus, through reinfection or reactivation
of latent virus. In contrast, a therapeutic vaccine containing
whole virus or whole viral proteins would be expected
to induce symptomatic as well as asymptomatic CD8 T-
cell responses, thus boosting harmful as well as protective
immunity.Obviously,boostingharmfulimmunityshouldbe
avoided. This can be accomplished using an asymptomatic
epitope-based therapeutic vaccine.
Since we have previously shown that there is signiﬁcant
HSV-1-speciﬁc CD8 T-cell exhaustion during latency in
mice,itmaybeusefultocomplementthetherapeuticasymp-
tomatic epitope vaccine strategy with exhaustion-pathway
b l o c k a g e .T h i si sl i k e l yt or e s u l ti na ne v e ns t r o n g e rC D 8 + T
cell response in latently infected “symptomatic” individuals.
5. The New Vaccines: Multivalent
“Asymptomatic” Lipopeptide Vaccines
It has been demonstrated that immunizations with a single
immunodominant CD8+ CTL epitope, administered in
a suitably strong adjuvant, can protect MHC-haplotype-
identical inbred mice against genital herpes [31, 76]. The
MHC-haplotype-outbreed nature of the human population
obviously complicates the development of single peptide-
based vaccines. Bearing in mind the particular properties
that would be required in a prospective human peptide
vaccine,weconceivedastrategyinwhichvirus-speciﬁcCD4+
and CD8+ T cell responses could be generated in diﬀerent
haplotypesusingasingleoramixtureoflipopeptidevaccines
[2, 34, 77, 78].8 Clinical and Developmental Immunology
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Figure 2: Illustration of steps in developing an asymptomatic lipopeptides-base herpes vaccine. The lipopeptide vaccine formulation is
developed following multistep strategy. This starts from the identiﬁcation of a symptomatic and asymptomatic herpes population and
highly immunogenic HSV proteins. Next, asymptomatic CD4+ and CD8+ T-cell epitopes are discovered and covalently linked to a TLR2
agonist (Palmitic acid) leading to self-adjuvanting lipopeptides [12].
Though subunit vaccines with a combination of pro-
tective epitopes are promising, several challenges are still
associated that need to be addressed. (i) Adding many
epitopestogetherinacocktailcanlowerthedoseofeachone,
thereby reducing overall eﬃcacy. (ii) Some balances during
epitope selection must be considered in order to deal with
the highly variable MHC-haplotype human population so
that the immunogenicity and protection are not impaired or
lost. (iii) Since both antibody and cell-mediated responses
are necessary for full protection, it is important to control
which epitopes stimulate which type of response. In spite of
these challenges, we believe that among the current subunit
vaccine types, a multiepitope peptide vaccine is best suited
to provide the complex epitope combination necessary to
protect a wide variety of human populations.
In other systems, induction of simultaneous responses
against multiple epitopes derived from multiple Ags has
already been demonstrated. The immunogenicity of multi-
epitope constructs appears to be strongly inﬂuenced by a
number of diﬀerent variables, and the immunogenicity (or
antigenicity) of the same epitope expressed in the context
of diﬀerent vaccine constructs can vary over several orders
of magnitude. This situation underscores the necessity of a
systematic study of diﬀerent variables in order to establish
clear criteria for the optimal design of multiepitope vaccines
(reviewed in [79, 80]). To address this in the context
of herpes, we are designing and optimizing multiepitope
vaccines comprising a panel of CD8+ and CD4+ T-cell
epitopes derived from major herpes Ags as described in
Figure 2. These epitopes were identiﬁed by class I and class
II algorithm predictions and peptide binding/recognition
strategies and recognized by recall immune responses from
seropositive individuals as well as from HLA transgenic
mouse models [24]. Studies need to optimize the vaccine
eﬃcacy by (i) eliminating junctional epitopes and spaces
between epitopes, (ii) the eﬀect of ﬂanking regions, and (iii)
cellular targeting to Ag processing and presentation path-
ways. Recognition of individual epitopes is demonstrated
by immunogenicity assays utilizing HLA transgenic mice
and/or antigenicity assays using human APCs transfected
in vitro with the prototype vaccine. The simplest vaccine
conﬁguration capable of eﬀective delivery of the selected
sets of epitopes will also be determined. Subsequent studies
will identify the optimal vaccine delivery strategy for simul-
taneous induction of immune responses against multiple
epitopes and the appropriate vaccine formulation. Overall,
it is anticipated that these studies will deﬁne operational
rules for the design and optimization of multiepitope-based
vaccines.
The proﬁle of HSV antigens presented during diﬀerent
phases of herpes infection implies that an ideal vaccine must
be multivalent and capable of inducing multiimmune re-
sponses. Since the ﬁrst demonstration of the technology,
a few years ago, lipopeptide vaccines have emerged as a
promising method of vaccination. In a variety of experimen-
tal systems, lipopeptide vaccines have been shown not only
to induce potent immune responses but also to oﬀer
many advantages in terms of ease of construction, testing,
and production (Figure 3). In the following paragraph
we summarize the progress achieved in developing aClinical and Developmental Immunology 9
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Figure 3: A representative diagram showing the advantages of lipopeptide-based vaccines strategy, as elaborated in the text (see Section 6).
lipopeptide-based vaccine that protects a progestin-induced
susceptible mouse model of genital herpes from infection
following intravaginal infection with either HSV-1 or HSV-
2. We describe initial studies of immunogenicity and outline
the strategies being employed to design the next generation
of lipopeptide vaccines.
A presumed advantage of lipopeptide immunogens is the
possibility of producing multivalent vaccines by a simple
physical mixture and simultaneous delivery of lipopeptides
bearing epitopes derived from one or more Ags, rather
than chemical covalent association of T-cell epitopes in one
molecule [81, 82]. Besides easy construction, such a mixture
may also prove more eﬀective than separate vaccines for each
epitope. These results in mice coincide with a recent clinical
trial of HIV-1 vaccine with similar strategy. The results
showed that up to six T-cell lipopeptides, selected from
three diﬀerent HIV proteins (Gag, Nef, and Env) delivered
simultaneously as a cocktail, were strongly immunogenic
in humans [81, 83]. These ﬁndings are also in line with a
recent report showing that immunization with a mixture of
six lipopeptides derived from four malaria Ags is eﬀective
in inducing multispeciﬁc CD4+ Th1 cells, CD8+ CTLs, and
IgG responses in nonselected “outbred” human populations
[81, 82].
Shortcomings in developing an eﬀective immunization
strategy against genital herpes include an imperative require-
ment for a safe Ag delivery system [39]. In most cases,
unmodiﬁed nonvectorized peptide Ags fail to elicit virus-
speciﬁc T cells, unless they are attached to a carrier protein
or delivered with a strong adjuvant [84–86]. Often, the
deliveryofpeptidesinthismannerisunsafeand/orpromotes
Th2 responses [87, 88], which would not be expected to
provideoptimalprotectionagainstHSVinfection[89].Lipid
tailing of peptides oﬀers a safe formulation that gener-
ates CD4+ T cells, CD8+ T, cells and Ab responses in the
absence of any adjuvant, apart from the lipid moiety itself
[81, 83, 90–94].
Physicochemical safety and immunogenicity studies in
animal models and in two human phase I clinical trials
have established the safety and eﬃcacy of HIV and malaria
lipopeptide vaccine candidates [81, 83, 90–94]. The present
paper focuses on herpes lipopeptides and demonstrates
their safety and ability to induce CD4+ Th1 cell-dependent
protective immunity against genital herpes when delivered
in water via a parenteral route. Since HSV-1 and HSV-2
invade human mucosa, delivery of Ags through the IVAG
route would induce better protection against these sexually
transmitted infections [95, 96]. We previously demonstrated
that intranasally administered lipopeptide epitopes induce
both mucosal and systemic B- and CD4+ Th1-cell responses
[2, 32–34, 97–100]. Similar results were obtained using the
human cytomegalovirus pp65-derived CD8+ CTL lipopep-
tides in which higher levels of virus-speciﬁc CTL were
obtainedwithlipopeptidedeliveredmucosally[2,32–34,97–
101]. Assessing the immunogenicity and protective eﬃcacy
of HSV-1 and HSV-2 lipopeptides following administration
through the IVAG or other mucosal routes (e.g., topical
ocular,sublingual,intranasal,orintrarectal)isbeingpursued
in our laboratory and will be addressed in future paper.
5.1. Advantages of Asymptomatic Epitope-Based Vaccines
(1) exclusion of potentially harmful symptomatic epi-
topes,
(2) focused immune response against immunodominant
and protective asymptomatic epitopes,
(3) molecularly deﬁned-no immunoevasion or patho-
genic molecules.10 Clinical and Developmental Immunology
Ourlipopeptidevaccineconstructismolecularlydeﬁned,
which makes it a particularly advantageous approach com-
pared to other vaccine strategies (see Tables 1 and 2).
Because the lipopeptide vaccine is constructed of chosen
asymptomatic epitopes, we are able to exclude symptomatic
epitopes that would otherwise reduce its eﬃcacy or the
harmful side eﬀects. The “symptomatic” epitopes may direct
T-cell responses away from those that are best suited to
clear the viral infection with minimal pathogenic reaction
(Figures 2 and 3 and [5]). An immunopathogenic T-cell
responsemightoccurthroughstimulatinglow-aﬃnityoligo-
clonal responses that inhibit broad-based T-cell responses
to other well-presented high-aﬃnity epitopes, thus deviating
protective responses to damaging responses. While protein-
based vaccines contain both symptomatic and asymptomatic
epitopes from the same protein, our lipopeptides exclusively
contain CD4 and CD8 asymptomatic epitopes from one or
many herpetic proteins [12]. Because symptomatic epitopes
can have pathological eﬀects when used in a vaccine, our
group has made it a priority to identify the asymptomatic
epitopes of HSV glycoproteins, tegument proteins, and
regulatory proteins [33, 67, 74, 77]. The lipopeptide vac-
cine has the fewest side eﬀects compared to the majority
of vaccine strategies so far used in clinical trials [102]
(Table 2). In addition, while all the other vaccines induce
a variety of speciﬁc CD4+ and CD8+ T cell responses
including low-aﬃnity ones, lipopeptides induce a focused,
strong and long-lasting CD4+ and CD8+ Tc e l lr e s p o n s e
against the selected immunodominant asymptomatic epi-
topes only [12, 32]. The lipopeptide vaccine strategy also
excludes those HSV proteins that may enable the virus
to evade the host immune system. While live attenuated
virus vaccine, inactivated virus vaccine, or protein-adjuvant
based vaccines contain unknown and potentially harmful
molecules, lipopeptide vaccines are molecularly deﬁned
and do not contain pathologic molecules, such as ICP-47
[103–105].
5.2. Mucosal Route of Vaccination. Mucosal surfaces con-
stitute an impressive ﬁrst-line defense that is frequently
exposed to HSV-1 and HSV-2 infections [106–109]. The
mucosal immune system is largely separate and distinct
from the systemic immune system [106–108] and is more
complex [106–108]. The tissue compartments involved in
mucosal immunity are mucosal inductive sites and mucosal
eﬀector sites. The inductive sites are comprised of lymphoid
tissue, where the triggering of na¨ ıve immune cells and the
generation of memory-eﬀector cells take place. This is where
Ags are encountered, taken up by APCs, processed, and
presentedtoBandTcells,whichmaythenmigratetoeﬀector
sites where immune T cells function [106–108]. Mucosal
tissues mostly contain DCs, which have properties to opti-
mize Ag uptake, processing and T-cell stimulation [110–
115]. Mucosal subunit vaccines are designed for needle-free
application, therefore safe and cost eﬀective compared to
other vaccines. Eﬃcacy of mucosal vaccine has been well
established for the oral poliovirus vaccine, but today very
few other vaccines administered by the mucosal route are
available commercially. Tremendous research eﬀorts have
signiﬁcantly improved the classical approach used to create
these vaccines, and alternative methods of immunization
based on new concepts of mucosal immunity are being
developed.
6. The Unknown
Progress towards an eﬀective vaccine has stalled in the face
of many unknown questions and related to HSV-1 and
HSV-2 infection and immunity. Namely, (i) the cellular and
molecular mechanisms behind the failure of past herpes
vaccines remain unknown, (ii) the cellular and molecular
mechanisms that lead the majority of HSV seropositive
individuals (i.e., asymptomatic individuals) to be naturally
“protected” exhibiting few or no recurrent clinical disease
while other HSV seropositive individuals (i.e., symptomatic
individuals) to have frequent ocular, orofacial, and/or genital
herpes clinical episodes remain unknown, (iii) HSV-speciﬁc
CD8+ T cells, selectively activated and retained in latently
infected trigeminal and sacral ganglia [34, 74, 116, 117],
play a crucial role in suppressing full blown reactivation of
HSV-1/2 latency [103, 116], apparently by interfering with
virus replication and spread following the initial molec-
ular events of reactivation. Thus, rather than completely
eliminating the latent HSV-1 from trigeminal and sacral
ganglia, reactivations appear to be “kept in check” by CD8+
T cells [12, 12, 74, 118]. The importance of CD8+ Tc e l l si n
providing constant immunosurveillance of latently infected
neurons, in which the virus starts to reactivate, is suggested
by numerous mouse, guinea pig, rabbit, and human studies
[34, 116, 119–122]. However, it is still unclear why and
how the virus manages to sporadically escape CD8+ Tc e l l -
mediatedimmunosurveillanceandeﬃcientlyreactivatefrom
latency to often cause ocular, orofacial, and genital herpes
diseases. Identiﬁcation of the immune evasion mechanism
used with HSV-1 and HSV-2 would certainly help develop
stronger preemptive immunotherapeutic vaccine strategies
against herpes.
In the past, dozens of vaccine immunotherapies have
tried to stimulate the immune system against herpes, in-
cluding about a dozen vaccines that reached mid- and
late-stage clinical trials. Every single one of these therapies
has generated much excitement, but, for the most part,
none of those therapies really did protect against herpes.
Before devising more powerful treatments it is imperative
to identify (i) the mechanisms underlying the suboptimal
nonprotective immunity associated with natural infection,
(ii) the major eﬀectors of immunity that control each of the
three phases of herpes infection (i.e., acute and latent), (iii)
the sophisticated immune evasion strategies employed by
HSV-1 and HSV-2 to dampen the immune response, (iv) the
protective versus pathogenic protein Ag(s) among more than
80 immunogenic HSV proteins, and (v) a safe Ag delivery
system.
Our laboratory is hoping to bridge some of the gaps in
our knowledge including (i) why CD4+ and CD8+ Tc e l l s
from asymptomatic and symptomatic individuals tend to
recognize diﬀerent sets of nonoverlapping HSV Ag epitopes;
(ii) Are the epitopes recognized by CD4+ and CD8+ TClinical and Developmental Immunology 11
cells from asymptomatic individuals protective against virus
replication, herpetic disease, and/or latent infection? (iii)
Can the magnitude of CD4+ and CD8+ T-cell responses
to “asymptomatic” human T-cell epitopes be signiﬁcantly
improved by epitope enhancement (increasing HLA binding
aﬃnity) or increasing their bioavailability (increase resis-
tancetoproteolysis)?(iv)Canthecombinationof“improved
asymptomatic T-cell epitopes” broaden the ocular immune
responses?(v)Canamultivalentlipopeptidevaccine,bearing
combination of “improved symptomatic CD4+ and CD8+
T-cell epitopes,” delivered intranasally, topically to the eyes,
or intranasally induce robust local immunity? (vi) Can local
HSV-speciﬁc immunity induced at the sites of infection
(i.e., the eye, the genital tract, trigeminal ganglia, and sacral
ganglia) or in the draining lymph nodes prevent virus
transmission/reactivation and/or limit the severity of ocular
and genital herpes?
A targeted immunotherapeutic vaccine is necessary to
induce robust localized immune responses (i.e., in central
nervous system, spinal cord, trigeminal ganglia, and sacral
ganglia), to quell virus replication, drive the pathogen into
a “latent” state, and likely hinder viral reactivation. However,
animmuneresponseinthecentralnervoussystemmightnot
be good. The release of inﬂammatory mediators including
reactive oxygen species may cause cell death in the central
nervous system (CNS). However the death from HSV-1-
mediated frank sporadic encephalitis is a rare event. A good
understandingofthecontributionofresidentandinﬁltrating
leukocytes within the nervous system in response to herpes
infection is necessary to identify candidate “asymptomatic”
epitopes and immune molecules, which do not induce
unwarranted inﬂammation coinciding with the maintenance
of the antiviral state.
We believe that in the next ﬁve years research should
focuson(1)identifyingmore“asymptomatic”versus“symp-
tomatic” herpes epitopes, (2) qualitatively and quantitatively
analyzing T cells in symptomatic versus asymptomatic
patients that could break new ground in our understanding
of the immune mechanisms underlying herpes pathogenesis
in humans, (3) incorporating only promiscuous “asymp-
tomatic” epitopes into vaccines, (4) using mucosal vaccine
strategies, such as lipopeptides, to immunize against herpes,
and(5)Using“humanized”susceptibleHLAtransgenicmice
and rabbits to assess the immunogenicity and protective
eﬃcacy of herpes epitopes against primary and recurrent
infection.
Future herpes vaccines should use a needle-free mucosal
application in which the epitopes are recognized by and
stimulate the mucosal immune system. We recently found
that synthetic peptide epitopes extended with an agonist
of Toll-like receptor 2 (TLR-2), which is abundantly
expressed on dendritic and epithelial cells of the vaginal
and ocular mucosa, can lead to induction of protective
immunity against herpes [123, 124]. Thus mucosal (topical
ocular or intravaginal) immunization with self-adjuvanting
lipid-tailed peptides bearing “asymptomatic epitopes”
appears to have attractive practical and immunological
features.
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